他克莫司联合激素治疗特发性膜性肾病.docVIP

他克莫司联合激素治疗特发性膜性肾病 　　【摘要】 目的：观察特发性膜性肾病采用他克莫司联合激素进行治疗的效果。方法：抽取2012年9月1日-2015年9月1日笔者所在医院收治的88例特发性膜性肾病患者作为研究对象，分成观察组与对照组，对照组采用激素联合环磷酰胺进行治疗，观察组采用激素联合他克莫司进行治疗，对比两组患者治疗效果。结果：用药后，观察组的血清白蛋白高于对照组，24 h蛋白尿低于对照组（P0.05）；观察组与对照组治疗有效率分别为90.91%、72.73%，观察组治疗效果较优（P0.05）；观察组与对照组不良反应发生率为27.27%、45.45%，观察组不良反应较低（P0.05）。结论：他克莫司联合激素对特发性膜性肾病进行治疗，具有疗效好、安全性高等优势，可为临床治疗提供良好的依据。 　　【关键词】 特发性膜性肾病； 激素； 他克莫司 　　中图分类号 R692 文献标识码 B 文章编号 1674-6805（2016）11-0022-03 　　【Abstract】 Objective：To observe the therapy effect of Tacrolimus combined with Hormone in the treatment of idiopathic peritoneal nephropathy.Method：From September 1，2012 to September 1，2015，88 patients with idiopathic peritoneal kidney disease were selected as the research objects，they were divided into the observation group and the control group，the control group was given Hormone combined with Cyclophosphamide treatment，the observation group was treated with Hormone joint Tacrolimus，the therapeutic effects of two groups were compared.Result：After medication，the serum albumin in the observation group was higher than that in the control group，24 h proteinuria was lower than the control group（P0.05），the treatment effectiveness in the observation group and the control group were 90.91%，72.73% respectively，the observation group had a better therapeutic effect（P0.05），the incidence of adverse reactions in the observation group and the control group were 27.27%，45.45% respectively，the observation group was lower than the control group（P0.05）.Conclusion：Tacrolimus combined with Hormone in the treatment of idiopathic membranous nephropathy has good curative effect，high security advantages，which provide a good basis for clinical treatment. 　　【Key words】 Idiopathic membranous nephropathy； Hormone； Tacrolimus 　　First-author’s address：Mianyang City Hospital of Traditional Chinese Medicine，Mianyang 621000，China 　　doi：10.14033/j.cnki.cfmr.2016.11.012 　　特发性膜性肾病是构成中老年患者原发性肾病综合征的常见疾病，80%表现为肾病综合征，其余为无症状蛋白尿，部分患者有镜下血尿，临床治疗方式以抑制炎症及免疫等为主[1]。为了提高特发性膜性肾病患